Navigation Links
Karyopharm Therapeutics Inc. Closes $20 Million Series A Financing to Advance Pipeline of Novel Nuclear Transport Modulators for Cancer, Inflammation and Other Disorders
Date:11/3/2010

NEWTON, Mass., Nov. 3, 2010 /PRNewswire/ -- Karyopharm Therapeutics Inc., a leader in the new field of nuclear transport modulators, has completed a $20M Series A financing. The nuclear transport machinery plays an integral role in the regulation of many molecules involved in a broad spectrum of human and animal disease. Karyopharm is focused on the discovery and development of novel selective inhibitors of nuclear export (SINE) for the treatment of cancer, autoimmune diseases and HIV.  These SINEs act by forcing the nuclear localization of major tumor suppressor and growth regulatory proteins, causing selective death of cancer cells, while sparing normal cells. The Karyopharm platform, utilizing rapid chemical optimization with integrated computational/in silico rational drug design, has yielded multiple novel active small molecule SINEs, which have shown activity in animal models of cancer.

The Series A financing, which follows approximately $1M in Angel investments, will be used to expand Karyopharm's research and development platform and to drive its first drug candidates into the clinic.  Sharon Shacham, PhD, MBA, Karyopharm's CSO and Acting President, remarked, "With this financing, we are able to move decisively to select a clinical candidate for our first indication in cancer. We believe that SINEs represent a completely new and highly effective approach to the treatment of cancers and other diseases with major unmet need.  Preclinical studies of our advanced SINEs have shown impressive single agent activity and synergy in combination with specific anti-cancer drugs while exhibiting good tolerability in animal models."

By inhibiting the nuclear export of tumor suppressor proteins, Karyopharm's drug candidates force the activation of the cell's own key regulatory pathways including those activated by p53, p27, pRB, BRACA1/2, FoxO, and the inhibitor of NF-kB (i.e., IkB). According to Karyopharm Co-Founder, Ronald A. DePinho, M.D., "The targeting of single molecules have provided marginal advances in cancer.  By blocking the export of multiple tumor suppressor proteins, this strategic point of intervention can impact on multiple pathways which cooperate to maintain tumors.  As normal cells want to keep these proteins in the nucleus, these SINEs should also exhibit an excellent safety profile in patients."

Following the Series A investment, Drs. Mansoor Raza Mirza, Ronald DePinho, and Michael Kauffman will comprise the Board of Directors.  Dr. Mirza, M.D. is Chief Oncologist at the Department of Oncology, Rigshospitalet - the Copenhagen University Hospital, Denmark.  Dr. DePinho is the Director of the Belfer Institute for Applied Cancer Science and Professor of Medicine and Genetics at the Dana-Farber Cancer Institute and Harvard Medical School. Dr. Giulio Draetta, M.D., Ph.D., a leader in cancer drug development, is Deputy Director of the Belfer Institute and Chief Research Business Officer at the Dana-Farber Cancer Institute.  Dr. Draetta will chair the Scientific Advisory Board.

About Karyopharm Therapeutics Inc.

Karyopharm is a privately held oncology company headquartered in Newton, Massachusetts. The Company was founded in 2009 by Drs. Sharon Shacham, Michael Kauffman, Ronald DePinho, and Giulio Draetta.  Karyopharm's founding team and scientific advisory board have demonstrated entrepreneurial success in developing project ideas to productive clinical outcomes. The company is focused on the development of modulators of nuclear transport as novel therapies for cancer, inflammatory and other diseases.  With the recent determination of the 3-dimensional structure of the nuclear pore complex, the mechanisms of nuclear transport have become more apparent.  Many key tumor suppressor and growth regulatory proteins are exported from the nucleus by the major export protein CRM1. Using its proprietary computational chemistry platform, Karyopharm has rapidly discovered and optimized a series of selective inhibitors of nuclear export (SINE) targeting the CRM1 protein.  Additional programs focused on other aspects of nuclear export, as well as nuclear import, have been initiated.

http://www.karyopharm.com

Contact: mkauffman@karyopharm.com


'/>"/>
SOURCE Karyopharm Therapeutics Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Talecris Biotherapeutics Launches PROLASTIN®-C in Canada
2. Cell Therapeutics Awarded $977,917 in Grants Under the Therapeutic Discovery Tax Credit Program
3. Protalix BioTherapeutics Announces Preliminary Top-Line Positive Data from taliglucerase alfa Switchover Trial
4. Cell Therapeutics, Inc. (CTI) Submits European Marketing Authorization Application for Pixuvri®
5. Shield Therapeutics Signs Agreement With AOP Orphan for ST10-021
6. Echo Therapeutics to Present at the LifeTech Capital 1st Annual Miami Medical Investors Conference
7. GSK and Amicus Therapeutics Enter Exclusive Worldwide Agreement to Develop and Commercialize Amigal™ for Fabry Disease
8. Amicus Therapeutics to Host Conference Call and Webcast to Discuss Exclusive Worldwide Agreement with GSK to Develop and Commercialize Amigal™ for Fabry Disease
9. Columbia University Students Learn About Pharmacy Benefit Management From Prime Therapeutics President and CEO
10. Cornerstone Therapeutics to Host Third Quarter 2010 Conference Call
11. Cell Therapeutics Third Quarter Net Loss Decreases by 68% in 2010 Compared to 2009
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/5/2016)... Ala. , Feb. 5, 2016  Patients in ... high intensity focused ultrasound (HIFU) therapy no longer have to ... to announce its partnership with Urology Centers of Alabama ... the newly FDA-cleared procedure for qualifying patients. ... their expertise in the treatment of prostate cancer using many ...
(Date:2/5/2016)... --> --> ... the global active pharmaceuticals ingredients (APIs) market stood at ... US$185.9 bn by 2020. It is expected to expand ... The title of the report is "Active Pharmaceutical Ingredients ... by Therapeutic Area) - Global Industry Analysis, Size, Share, ...
(Date:2/5/2016)... HARROGATE, England , February 5, 2016 ... --> Today, VoicePower Ltd - The Speech Recognition People, ... has been deployed to improve patient care, reduce turnaround times and ... ,- Wirral CCG ,- VoicePower client since 2013 Challenge: ... Challenge: --> - Six doctors ,- Wirral ...
Breaking Medicine Technology:
(Date:2/5/2016)... San Rafael, CA (PRWEB) , ... February 05, 2016 , ... ... partnership with ChildLight Yoga Studio in Dover, NH to direct high-performance kids yoga training. ... on New Hampshire’s seacoast, just one hour from Boston. , ChildLight Yoga Studio founder ...
(Date:2/5/2016)... New York, New York (PRWEB) , ... February 05, 2016 , ... ... in gym use and find themselves having to wait longer to access the treadmills. ... on their New Year’s resolutions to lose weight and get in shape by joining ...
(Date:2/5/2016)... ... February 05, 2016 , ... Pivot Point Consulting, a leading ... Software & Services for HIT Implementation Support & Staffing report with an outstanding ... performance by healthcare executives, managers and clinicians representing over 4,500 hospitals and 2,500 ...
(Date:2/5/2016)... ... 2016 , ... Stuart Bentkover, MD, FACS is thrilled to announce ... most effective tattoo removal today, Dr. Bentkover is the only doctor in Central Massachusetts ... PicoSure has been approved by the Food and Drug Administration (FDA) as a safe ...
(Date:2/5/2016)... ... 05, 2016 , ... In sleep, when the defenses of the day are ... of patients with eating disorders is significant self-criticism, and consequently these patients experience this ... regarded as maladaptive means for coping with this unease, but also leads to a ...
Breaking Medicine News(10 mins):